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DOI 10.1016/j.ccr.2010.02.030SUMMARYHigh Gleason grade prostate carcinomas are aggressive, poorly differentiated tumors that exhibit diminished
estrogen receptor b (ERb) expression. We report that a key function of ERb and its specific ligand 5a-andros-
tane-3b,17b-diol (3b-adiol) is to maintain an epithelial phenotype and repress mesenchymal characteristics
in prostate carcinoma. Stimuli (TGF-b and hypoxia) that induce an epithelial-mesenchymal transition (EMT)
diminish ERb expression, and loss of ERb is sufficient to promote an EMT. The mechanism involves ERb-
mediated destabilization of HIF-1a and transcriptional repression of VEGF-A. The VEGF-A receptor neuropi-
lin-1 drives the EMT by promoting Snail1 nuclear localization. Importantly, this mechanism is manifested in
high Gleason grade cancers, which exhibit significantly more HIF-1a and VEGF expression, and Snail1
nuclear localization compared to low Gleason grade cancers.INTRODUCTION
The Gleason grading system for prostate carcinoma (PCa) is
a key parameter that is extremely valuable for assessing prog-
nosis and choice of therapy (Gleason and Mellinger, 1974;
Egevad, 2008a; Egevad, 2008b). This system is based on the
grade of histological and cytological differentiationwithin a tumor
and provides a score that ranges from 1 (well-differentiated) to 5
(poorly differentiated). The combined total Gleason score for
a tumor, which is used to predict prognosis, reflects the sum of
the predominant and secondary grades observed in that cancer.
Grade 5 patterns are relatively uncommon and are more
frequently found as tertiary foci admixed with grade 4 and to a
lesser extentwith grade 3 cancers. The presence of tertiary grade
5 cancers within a tumor confers a poor outcome (Trpkov et al.,
2009), most likely because these cancers exhibit highly invasive
characteristics in histological sections (Gleason and Mellinger,
1974). For this reason, the International Society of Urological
Pathology has recommended that biopsy Gleason score beSignificance
The Gleason grading system for prostate cancer is based on th
assessing prognosis and choice of therapy. Although high Glea
the differentiation that underlies Gleason grading has not been
high from lowGleason grade tumors, is associated with the exp
HIF-1 and VEGF/neuropilin signaling. These findings should fac
the aggressive behavior exhibited by these high-grade cancer
peutic intervention.generated by adding tertiary grade 5 to the primary score to
provide a more accurate assessment of prognosis (Epstein
et al., 2005). A key biological issue that emerges from these
observations is the molecular basis for the histological differenti-
ation and range of invasiveness that underlies the Gleason
grading system. Although high Gleason grade PCa is character-
ized by a de-differentiated morphology, the possibility that the
progression of Gleason grade reflects, in part, the differential
expression of EMT pathways has not been pursued rigorously.
The potential role of estrogen receptors (ERs) in regulating
the epithelial-mesenchymal transition (EMT) and aggressive
behavior in PCa merits investigation. Although ERa can regulate
E-cadherin and theEMT inbreast cancer (Dhasarathy et al., 2007;
Wang et al., 2007), breast and prostate are different with respect
to ER expression and function (Morani et al., 2008). In fact, ERa is
predominantly localized in prostatic stroma where its effects on
epithelia are considered to be indirect (Prins and Korach, 2008).
In contrast, ERb (Kuiper and Gustafsson, 1997; Lau et al., 2000;
Leung et al., 2006; Prins et al., 1998) is expressed in the epitheliale degree of histological differentiation, and it is valuable for
son grades portend poor prognosis, the molecular basis for
defined.We now report that loss of ERb, which distinguishes
ression of an EMT program of dedifferentiation that involves
ilitate our understanding of the mechanisms responsible for
s and the development of effective methods for their thera-
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Figure 1. ERb1 and EMT of PCa
(A) Specimens of normal glandular epithelium,
Gleason grade 3 and 5 PCa were stained for
E-cadherin and ERb1 and photographed. ERb1 is
localized in the nuclei of basal cells in the normal
prostate and nuclei of grade 3 tumor cells (arrow).
In contrast, nuclear ERb1 staining is absent in
grade 5 PCa (arrow). The data are representative
of three separate specimens for each classifica-
tion. Scale bars represent 20 mm.
(B) PC3 cells were treated with phosphate-
buffered saline (con) or TGF-b for 3 days, photo-
graphed and extracts were analyzed for the
expression of EMTmarkers and ERb1 by immuno-
blotting.
(C, D) PC3 (C) or LNCaP (D) cells were maintained
in either normoxia (N) or hypoxia (H) (0.5% O2)
for 24 hr and then photographed, and extracts
from these cells were immunoblotted as described
above. Scale bars represent 50 mm. See also
Figure S1.
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ERb Impedes Prostate Carcinoma EMTcompartment of the gland and may regulate epithelial prolifera-
tion and differentiation (Imamov et al., 2004). The expression
pattern of ERb in human PCa is of interest because there is an
inverse relationship between the expression of ERb and the
progression of PCa to highly aggressive Gleason grades (Leav
et al., 2001; Zhu et al., 2004). Given these data, we hypothesized
that ERb functions as a ‘‘gatekeeper’’ of the epithelial phenotype
and a repressor of invasion and sought to elucidate the mecha-
nisms involved in ERb-mediated regulation of EMT in PCa.
RESULTS
ERb1 Sustains an Epithelial Phenotype and Represses
Mesenchymal Characteristics
Gleason grade 5 PCa is distinguished from grade 3 PCa by
a merger of neoplastic glands and cytological de-differentiation320 Cancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc.(Gleason and Mellinger, 1974) with dimin-
ished expression of ERb (Horvath et al.,
2001; Leav et al., 2001; Zhu et al., 2004),
as well as E-cadherin (Gravdal et al.,
2007; Tomita et al., 2000) (Figure 1A).
Thus, we hypothesized that ERb actually
regulates the EMT in PCa and that
high Gleason grade cancers exhibit EMT
characteristics associated with dimin-
ished ERb1 expression. To address this
hypothesis, we used PC3 cells initially
because these androgen-independent
cells express E-cadherin and ERb, and
exhibit epithelial characteristics (Fig-
ure 1B). We focused on ERb1 because it
is the only functional ERb isoform (Leung
et al., 2006). Treatment of PC3 cells with
TGF-b (Figure 1B) or exposure to hypoxia
(Figure 1C) resulted in the transition to
a dispersed, fusiform morphology, signif-
icant loss of E-cadherin and increasedexpression of vimentin and N-cadherin. These results were
substantiated by immunofluorescence microscopy (see Fig-
ure S1 available online). Similar data were obtained with LNCaP
cells (Figure 1D), which also exhibit epithelial features but are
androgen dependent, indicating that the ability of microenviron-
mental stimuli to induce an EMT is independent of androgen
receptor status (Figure 1D).
A striking observation was that both TGF-b and hypoxia mark-
edly decreased ERb1 expression without affecting ERa (Figures
1B and 1C), suggesting that loss of this ER promotes an EMT in
PCa. To assess whether ERb1 plays a causal role in the EMT,
stable clones of PC3 cells were generated that express an
ERb1 shRNA and exhibit diminished ERb1 expression (Figures
2A and 2B). These cells have a fusiform morphology, diminished
E-cadherin and increased expression of vimentin and N-cad-
herin in comparison to parental cells or cells that express
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Figure 2. ERb1 Sustains an Epithelial
Phenotype and Impedes EMT in PCa
(A) PC3 cells that express either an ERb1 shRNA
(shERb1) or scrambled shRNA (shCon) or parental
cells were photographed.
(B) Extracts of these cells were immunoblotted for
ERb1 and EMT markers.
(C) Extracts of PC3 cells that express either an ERa
siRNA (siERa) or a scrambled siRNA (Scr) were
immunoblotted for E-cadherin, N-cadherin, ERa,
and ERb1.
(D) The relative expression of E-cadherin and
vimentin was assayed in PC3 cells that stably
express either a control shRNA or ERb1 shRNA
by qPCR using PGK1 as an internal control. The
data represent the average of two experiments.
(E) PC3 cells expressing a scrambled shRNA (Scr)
or an ERb1 shRNA (shERb1) were transfected with
an E-cadherin promoter reporter construct (Scr+
and shERb1+) or pGL2 Basic vector as a control
(Scr and shERb1) and assayed for luciferase
activity. The data represent the mean of Firefly
luciferase activity normalized to Renilla from three
separate experiments (± standard error of the
mean [SEM]) with p value (*) < 0.05.
(F) PC3 cells that express either a control shRNA
(shCon) or ERb1 shRNA (shERb1) were assessed
for their ability to either migrate or invade. The
data represent the mean of three separate experi-
ments (±SEM) with p value (*) < 0.05.
(G) PC3 cells transfected with either control siRNA
(siCon) or ERb1 SMARTpool siRNA (siERb1) and
the parental cells were examined for morphology
and EMT marker expression after 3 days. Scale
bars represent 50 mm.
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ERb Impedes Prostate Carcinoma EMTa scrambled shRNA (Figures 2A and 2B). In contrast, siRNA-
mediated repression of ERa did not affect morphology (data
not shown) or the expression of EMTmarkers (Figure 2C). Quan-
titative real time-PCR (qPCR) revealed that loss of ERb1
increased expression of vimentin mRNA and decreased E-cad-
herin mRNA significantly (Figure 2D). To establish that ERb1
regulates E-cadherin transcription, we assayed E-cadherin pro-
moter activity in cells that expressed either ERb1 shRNA
(‘‘knockdown’’ cells) or a scrambled shRNA (control cells) using
a reporter construct containing the E-cadherin promoter. As
shown in Figure 2E, ERb1 knockdown cells had substantially
diminished promoter activity compared with control cells.
Loss of ERb1 expression also resulted in a significant increase
in migration and invasion (Figure 2F), functions characteristic
of an EMT (Yang andWeinberg, 2008). To exclude the possibility
of clonal artifacts during the selection of stable cell lines, we used
ansiRNApool forERb1 that yieldedsimilar effectsonmorphology
and expression of mesenchymal markers as did the shRNA
(Figure 2G). These RNAi data were substantiated using PHTPPCancer Cell 17, 319–3(Figure 3, a highly selective ERb antago-
nist (Compton et al., 2004). Treatment of
PC3 cells with PHTPP resulted in the
acquisition of a spindle-shaped morphol-
ogy, diminished expression of E-cadherin
and increased expression of N-cadherinand vimentin (Figure 3A). Collectively, these data indicate that
ERb1 expression is required to maintain an epithelial phenotype
in PCa cells and that an endogenous ERb1 ligand for is engaged
in this process.
5a-Androstane-3b, 17b-diol (3b-Adiol), an ERb Ligand,
Sustains an Epithelial Phenotype and Impedes
a Mesenchymal Transition in PCa Cells
An important issue is the identification of the ERb1-specific
ligand that sustains an epithelial phenotype and impedes an
EMT in PCa cells. Although ERb1 binds estradiol-17b (E2), there
is evidence that 3b-adiol, a metabolite of dihydrotestosterone,
is the natural ligand of ERb1 in the prostate (Guerini et al.,
2005). To evaluate the function of this ligand, PC3 cells were
treated with either dimethyl sulfoxide (DMSO) or 3b-adiol for
3 days. As shown in Figure 3B, 3b-adiol treatment resulted in a
more compact, epithelial morphology, consistent with increased
expression of E-cadherin, and diminished expression of N-cad-
herin and vimentin. In contrast, treatment with DMSO had no32, April 13, 2010 ª2010 Elsevier Inc. 321
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Figure 3. The ERb1 Ligand 3b-Adiol
Sustains an Epithelial Phenotype in PCa
PC3 cells were incubated with either DMSO (Con),
the ERb1 antagonist PHTPP (A), or 3b-adiol (B) for
3 days, and morphology and EMT marker expres-
sion were examined. PC3 cells were treated with
TGF-b in the absence or presence of estradiol-
17b (E2) (10 nM) or 3b-adiol (1 mM) and examined
for morphology (C) and expression of ERb1 and
EMT markers (D, left panel). Cells treated in the
absence or presence of TGF-b were also exam-
ined for ERb1 transcripts by RT-PCR (D, right
panel). ERb1 knockdown cells (shERb1) untreated
or treated with either 3b-adiol (1 mM) or E2 (10 nM)
were examined for morphology and expression of
EMT markers (E). Scale bars represent 50 mm.
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ERb Impedes Prostate Carcinoma EMTsignificant effect on either morphology or expression of EMT
markers. Moreover, cells treated with 3b-adiol but not E2 were
unable to undergo TGF-b-induced EMT as evidenced by
morphology and expression of EMT markers (Figures 3C and
3D). We also observed that 3b-adiol prevented the diminution
in ERb1 expression that occurs in response to TGF-b stimulation
(Figure 3D), suggesting that 3b-adiol prevents an EMT by
stabilizing ERb1 and enabling it to function to sustain an epithe-
lial phenotype. This hypothesis is further supported by the
observation that 3b-adiol treatment did not affect expression
of ERb1 mRNA during TGF-b-induced EMT (Figure 3D) and
that methylation of the ERb1 promoter, which has been shown
to regulate its expression (Zhu et al., 2004), did not change
during this EMT (data not shown). The specificity of 3b-adiol
for ERb1 in maintaining an epithelial phenotype is evidenced
by the inability of this ligand to impede an EMT in cells lacking
ERb1 (Figure 3E).322 Cancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc.HIF-1a Is Destabilized by ERb1 via
Proteasomal Degradation
Based on our findings that either loss of
ERb1 expression or hypoxia induces
EMT and that hypoxia diminishes ERb1
expression, we assessed a possible rela-
tionship between ERb1 andHIF-1. HIF-1a
protein expression is low in PC3 cells but
it increased markedly in response to
either hypoxia, TGF-b stimulation, knock-
down of ERb1 with both shRNA and
siRNA, or PHTPP (Figure 4A). However,
expression of HIF-1a transcripts did not
change under these conditions (Figure
4A), suggesting that ERb1 destabilizes
HIF-1a protein via proteasomal degrada-
tion. To test this hypothesis, we examined
HIF-a protein expression in control PC3
cells and ERb1 knockdown cells in either
the absence or presence of the protea-
some inhibitor MG132. MG132 increased
HIF-1a expression dramatically in control
cells, but neither E2 nor 3b-adiol had an
effect (Figure 4B). In comparison, the
elevated level of HIF-1a in ERb1 knock-down cells was not affected by MG132, E2, or 3b-adiol
(Figure 4B). Importantly, control cells but not ERb1 knockdown
cells treated with MG132 converted from an epithelial to
a mesenchymal phenotype, as evidenced by morphology and
expression of EMT markers (Figure 4C). These data strongly
suggest that ERb1 destabilizes HIF-1a protein via proteasomal
degradation.
ERb1 and 3b-Adiol Repress HIF-1-Mediated
Transcription of VEGF-A
We hypothesized that VEGF-A is a HIF-1 target gene important
for the EMT of PCa that is regulated by 3b-adiol/ERb1. To pursue
this possibility, we assessed VEGF-A expression by qPCR in
either control PC3 cells or ERb1 knockdown cells and observed
that ERb1 suppresses VEGF-A expression significantly (Fig-
ure 4D). TGF-b also induces a dramatic increase in VEGF-A
expression (Figure 4D). Interestingly, 3b-adiol attenuated
Cancer Cell
ERb Impedes Prostate Carcinoma EMTVEGF-A expression in PC3 cells and it prevented the ability of
TGF-b to increase VEGF-A expression (Figure 4D). These effects
of 3b-adiol were partially blocked by PHTPP, further supporting
the notion that the interaction of 3b-adiol with ERb1 represses
VEGF-A expression. To confirm that ERb1 regulates VEGF-A
secretion, we quantified VEGF-A expression in culture medium
by enzyme-linked immunosorbent assay (ELISA). Indeed, both
TGF-b and loss of ERb1 increased VEGF-A secretion markedly
(Figure 4E).
To elucidate themechanism of how ERb1 suppresses VEGF-A
expression, we measured VEGF-A promoter activity in PC3 cells
using a reporter construct containing the full-length VEGF-A
promoter, which contains an estrogen response element (ERE)
and a hypoxia response element (HRE) (Stevens et al., 2003).
The latter element is a key regulator of VEGF-A transcription
(Liao and Johnson, 2007). The luciferase activity of this reporter
construct was significantly higher in ERb1 knockdown cells
compared with control cells, suggesting that ERb1 is required
to suppress promoter activity (Figure 4F). Cells treated with
TGF-b also had elevated promoter activity compared with
untreated cells (Figure 4F). Interestingly, mutating the ERE in
this promoter construct increased luciferase activity, supporting
our hypothesis that ERb1 acts as a repressor of VEGF-A tran-
scription via the ERE (Figure 4F). Moreover, mutating both the
ERE and HRE abrogated the increase in transcription observed
with the ERE mutant alone (Figure 4F), arguing that the HRE
contributes to the de-repression of transcription that occurs
when the ERE is mutated. We then examined the role of ERb1 it-
self in regulating HRE-mediated transcription of VEGF-A in
hypoxia by expressing reporter constructs containing only
wild-type or mutated HRE and no ERE in both control and
ERb1 knockdown cells. As shown in Figure 4G, loss of ERb1
under hypoxic conditions stimulated transcription significantly
as compared with the control cells. However, promoter activity
in both cell lines was attenuated when the HRE was mutated.
Together with the other data shown in Figure 4, we conclude
that ERb1 represses VEGF-A transcription directly using the
ERE and indirectly by destabilizing HIF-1a and repressing HIF-
1-mediated transcription.VEGF-A and Neuropilin-1 Promote an EMT
The possibility that VEGF-A promotes an EMT is demonstrated
by the finding that treatment of PC3 cells with recombinant
VEGF165 resulted in a fusiform morphology (Figure 5A),
decreased E-cadherin and increased expression of N-cadherin
and vimentin (Figure 5A). The expression of ERb1 did not change
indicating that the regulation of VEGF-A is downstream of ERb1
signaling. Autocrine VEGF signaling in tumor cells is a nonangio-
genicmechanism that contributes to their autonomy and aggres-
sive behavior (Bachelder et al., 2001; Bates et al., 2003; Cao
et al., 2008; Castro-Rivera et al., 2004). A key VEGF-A receptor
implicated in autocrine signaling is neuropilin-1 (NRP1) (Bach-
elder et al., 2001; Soker et al., 1998). In contrast to VEGF-A,
expression of NRP1 did not change in response to either EMT
stimuli or loss of ERb1 expression (data not shown). To elucidate
the function of NRP1 during an EMT, we generated NRP1 knock-
down PC3 cells using shRNA (Figure 5B). Strikingly, cells with
diminished NRP1 expression were resistant to EMT inductionby TGF-b treatment compared with control cells, as evidenced
by their morphology and expression of EMTmarkers (Figure 5B).The Activities of Akt and GSK-3b, which Regulate
the EMT, Are Controlled by ERb1 and 3b-Adiol
Given that NRP1 can regulate Akt/GSK-3b activity (Bachelder
et al., 2001) and that GSK-3b impedes an EMT (Zhou et al.,
2004; Bachelder et al., 2005; Yook et al., 2005, 2006), we exam-
ined the relationship between ERb1 and GSK-3b activation.
Phosphorylation of GSK-3b on Ser9 by Akt inactivates its kinase
activity (Doble andWoodgett, 2003). Treatment of PC3 cells with
TGF-b or exposure to hypoxia resulted in a significant increase in
the relative phosphorylation of both Akt and GSK-3b as as-
sessed by immunoblotting (Figure 5C). Similar results were ob-
tained with LNCaP cells and ERb1 knockdown cells (Figures
5C–5D). These data indicate that ERb1 sustains GSK-3b activa-
tion and that loss of its expression during an EMT activates the
pAkt/pGSK-3b pathway. To show that this signaling is ligand
dependent, cells were treated with either 3b-adiol or PHTPP,
and subsequently analyzed for GSK-3b activation. Cells treated
with 3b-adiol had a decrease in GSK-3b phosphorylation
compared with control, whereas cells treated with PHTPP had
a significant increase in GSK-3b phosphorylation (Figure 5E). In
contrast, E2 did not affect GSK-3b phosphorylation (data not
shown). These data strongly suggest that 3b-adiol is the endog-
enous ligand for ERb1 that sustains GSK-3b activation.Snail1 Nuclear Localization Is Regulated
by 3b-Adiol/ERb1 and VEGF-A/NRP1
Given that Snail1 expression in tumors often correlates with
aggressive disease and poor outcome (Blanco et al., 2002;
Moody et al., 2005; Wu et al., 2009), we were surprised that
Snail1 expression did not change in response to TGF-b, hypoxia,
VEGF-A, loss of ERb1, or NRP1 (Figures 1, 2, and 5). To assess
the potential role of Snail1 in the EMT, we used siRNA to
decrease its expression in ERb1 knockdown cells. Indeed,
reduction of Snail1 expression caused a reversion to a more
epithelial morphology and decreased the expression of vimentin
and N-cadherin with a concomitant increase in E-cadherin (Fig-
ure 6A). These observations and the finding that Snail1 stability
and nuclear localization can be regulated by phosphorylation
and EMT pathways (Dominguez et al., 2003; Yook et al., 2005;
Zhou et al., 2004) prompted us to assess the intracellular locali-
zation of Snail1. Surprisingly, the EMT induced by hypoxia,
VEGF-A, or TGF-bwas coincident with a significant translocation
of Snail1 from the cytoplasm to the nucleus as assessed by
immunofluorescence microscopy using a Snail1 Ab (Figures
6B–6C). This conclusion was strengthened by the finding that
loss of ERb1 resulted in a significant increase in the nuclear local-
ization of a GFP-Snail1 construct (Zhou et al., 2004) (Figure 6D).
In contrast, treatment of PC3 cells with 3b-adiol reduced the
basal localization of Snail1 in the nucleus significantly and it pre-
vented the increase in Snail1 nuclear localization that occurs in
response to TGF-b stimulation (Figure 6E). Importantly, treat-
ment with LiCl2, a GSK-3b inhibitor, increased the nuclear local-
ization of Snail1 significantly, providing evidence that the
signaling pathway that is repressed by ERb1 regulates Snail1
localization (Figure 6C).Cancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc. 323
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Figure 4. ERb1 Destabilizes HIF-1a Protein and Represses HIF-1-Mediated Transcription of VEGF-A
(A) PC3 cells maintained in either normoxia (N) or hypoxia (H) for 24 hr, treated with PBS (Con) or TGF-b, transfected with control or ERb1 shRNA or siRNA, or
treated with PHTPP were analyzed for the expression of HIF-1a by immunoblotting. *nonspecific band. HIF-1amRNA was detected by RT-PCR in TGF-b-stim-
ulated cells and shRNA transfected cells.
(B) PC3 cells (scrambled control cells) or ERb1 knockdown cells were treated in the absence or presence of MG132 (1 mM), 3b-adiol (1 mM), or E2 (10 nM) for 6 hr
and immunoblotted for HIF-1a.
(C) PC3 cells (scrambled control cells) or ERb1 knockdown cells were treated in the absence or presence of MG132 (1 mM) for 6 hr and photographed. Scale bars
represent 50 mm. Extracts of the control cells treated with MG132 were immunoblotted for E-cadherin, vimentin, and b-actin.
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ERb Impedes Prostate Carcinoma EMTHIF-1a/VEGF/Snail1 Pathway Is Manifested in High
Gleason Grade PCa
A critical question that arises from our in vitro data is whether
the expression of HIF-1a, VEGF-A, and nuclear Snail1 correlates
with Gleason grade in human PCa, and whether the expression
of these proteins correlates inversely with ERb1 in the same
specimens aspredicted by our hypothesis. To address this ques-
tion, we used a semiquantitative analysis of IHC staining to
assess expression of these proteins in specimens from 30 PCa
patients, of which 20 were Gleason grade 3 and 10 were grade
5. Expression of ERb1 was significantly higher in the nuclei of
grade 3 compared with grade 5 PCa (Figure 7A), confirming
previous studies (Horvath et al., 2001; Leav et al., 2001; Zhu
et al., 2004). In marked contrast, however, we observed intense,
widespread nuclear HIF-1a expression in grade 5 cells that was
significantly less in grade 3 cells (Figure 7B). Intense VEGF-A
immunostaining was evident in Gleason grade 5 tumor cells
when compared with grade 3 tumor cells, and semiquantitative
analysis of multiple specimens revealed that this difference is
significant (Figure 7C). This observation was strengthened by
qPCR analysis of VEGF-A expression from microdissected
specimens of human PCa, which demonstrated that grade 5
tumor cells had significantly higher VEGF-A mRNA expression
than did grade 3 tumor cells (Figure 7D).
Our data on Snail1 localization in vitro and its regulation by
ERb1 prompted us to compare Snail1 nuclear localization in
Gleason grade 3 and 5 PCa. In grade 3 PCa, only a scattered
number of positively stained nuclei were apparent. However,
intense widespread nuclear Snail1 staining was evident in the
majority of grade 5 tumor cells (Figure 7E) accompanied by
a decline in ERb1 expression. These results are consistent with
the hypothesis that ERb1 restricts Snail1 to the cytoplasm, but
it becomes translocated to the nucleus when receptor levels
decline.
We conclude from our data that a major function of the
3b-adiol/ERb1 complex in PCa is to impede a mesenchymal
transition and consequent invasive behavior by a mechanism
that involves its ability to destabilize HIF-1a and repress tran-
scription of VEGF-A, which drives an EMT by enhancing nuclear
localization of Snail1 (Figure 8). Most importantly, key features of
this pathway are manifested in high Gleason grade PCa.
DISCUSSION
Our data highlight a pivotal role for ERb1 and its natural ligand
3b-adiol in sustaining an epithelial phenotype and repressing
the acquisition of mesenchymal characteristics and invasive
behavior in PCa. The key mechanism that we elucidate to(D) PC3 cells expressing a scrambled shRNA (Scr) or an ERb1 shRNA (shERb1) we
treated with PBS (Con) or TGF-b in the absence or presence of 3b-adiol (1 mM) or 3
mRNA expression by qPCR (right graph).
(E) VEGF-A secretion in culture medium from PC3 cells treated with PBS (Con) o
(F) Scrambled control cells (Scr) or ERb1 knockdown cells (shERb1) were transfec
to Renilla was measured (left graph). PC3 cells were transfected with a wild-type
(WT+TGFb). Concurrently, cells were transfected with the reporter construct con
HREm) and normalized luciferase activity was measured (right graph).
(G) Scrambled control cells (Scr) or ERb1 knockdown cells (shERb) were transfect
amutated version of the HRE reporter construct: Scr (mut) or shERb (mut) under hy
All data are the mean of three separate experiments with SEM and p value (*) <account for this function of ERb1 is that it destabilizes HIF-1a
and represses transcription of VEGF-A, a growth factor that
can promote an EMT (Wanami et al., 2008; Yang et al., 2006).
The significance of our in vitro data is strengthened by the fact
that key components of this pathway we describe are detected
in high Gleason grade PCa, which is characterized by highly
invasive and aggressive behavior. Moreover, other studies
support the existence and clinical relevance of EMT-like
processes in PCa (e.g., Acevedo et al., 2007). Of note, a recent
study that compared gene expression during prostate develop-
ment with PCa suggested that those tumors with a transcript
profile consistent with branchingmorphogenesis, which involves
EMT, were likely to be invasive and have an early relapse after
surgical resection (Pritchard et al., 2009).
We identify 3b-adiol, a 5a-DHTmetabolite, as a specific ligand
for ERb1 that mediates the ability of this ER to sustain an epithe-
lial phenotype and repress EMT and invasion. 3b-Adiol binds to
ERb but not ERa or the androgen receptor (Kuiper et al., 1997).
Interestingly, E2, a ubiquitous ligand for both ERa and ERb,
was ineffective in regulating E-cadherin and the EMT. Our data
also suggest that an important function of 3b-adiol is to maintain
ERb expression, an observation alsomade in normal rat prostate
(Oliveira et al., 2007). These data strengthen the hypothesis that
3b-adiol is the primary ligand for ERb in the prostate and that its
major function is to maintain a differentiated, epithelial pheno-
type. This conclusion is supported by the fact that the concentra-
tion of 3b-adiol in the prostate gland is 100-fold higher than that
of E2 (Voigt and Bartsch, 1986).
The key mechanistic finding in our study is that ERb1
represses VEGF-A transcription by a complex mechanism that
involves its ability to regulate two key response elements within
the VEGF-A promoter: the ERE and the HRE. This finding is
distinct from studies demonstrating that E2 stimulates VEGF-A
transcription in the breast and uterus (Buteau-Lozano et al.,
2002; Hyder, 2006; Stoner et al., 2004). Our data suggest that
ERb1 represses VEGF-A transcription directly via the ERE,
a function that may require recruitment of corepressors such
as NCoR (Girault et al., 2003). Importantly, we also conclude
that ERb1 represses VEGF-A transcription indirectly by destabi-
lizing HIF-1a and impeding HIF-1-mediated transcription of
VEGF-A. This conclusion is supported by our proteasome inhib-
itor data and mutational analysis of the HRE and ERE in the
VEGF-A promoter, as well as the observation that ERb and
HIF-1a can associate physically (Lim et al., 2009).
We implicate VEGF-A as an ERb1-regulated HIF-1 target gene
that links 3b-adiol/ERb1 to Snail1 localization and the EMT. This
function of VEGF-A in PCa cells is of interest because the
hypothesis that VEGF and its receptors impact the behavior ofre analyzed for VEGF-AmRNA expression by qPCR (left graph). PC3 cells were
b-adiol (1 mM) plus PHTPP (5 mM). After 3 days, cells were analyzed for VEGF-A
r TGF-b or transfected with control or ERb1 shRNAs was quantified by ELISA.
ted with a VEGF promoter reporter construct and luciferase activity normalized
VEGF-A promoter reporter construct in the absence (Wt) or presence of TGF-b
taining either a mutated ERE (EREm) or both a mutated ERE and HRE (EREm/
ed either with a wild-type HRE reporter construct: Scr (Wt) or shERb (Wt) or with
poxic conditions for 16-18 hr and normalized luciferase activity wasmeasured.
0.05 indicated.
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Figure 5. VEGF-A Promotes EMT and the VEGF Receptor NRP1 Is Necessary for EMT and Regulates GSK-3b Activity
(A) PC3 cells were grown in RPMI medium in the absence or presence of recombinant VEGF165 (50 ng/ml) for 24 hr. Cells were photographed and extracts were
immunoblotted to assess expression of EMT markers.
(B) Photomicrographs of PC3 cells that express either an empty vector (shCon), GFP shRNA (shGFP) or two different NRP1 shRNAs (shNRP1A and shNRP1B)
were treated with or without TGF-b for 3 days. Extracts from these cells were immunoblotted for NRP1, as well as EMT markers.
(C) Extracts from PC3 cells stimulated with either TGF-b, normoxia (N) or hypoxia (H), or ERb1 knockdown cells (shERb1) were immunoblotted with Abs specific
for pAkt (Ser473), pGSK-3b (Ser9), Akt, GSK-3b, and b-actin.
(D) Extracts of LNCaP cells maintained in either normoxia (N) or hypoxia (H) for 24 hr were immunoblotted with the same Abs.
(E) PC3 cells were treated in the absence or presence of 3b-adiol or PHTPP and subsequently analyzed for phospho-GSK3b, total GSK3b and Snail1 expression.
Scale bars represent 50 mm.
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2001; Bates et al., 2003; Cao et al., 2008; Castro-Rivera et al.,
2004; Su et al., 2006). The significance of our results is that we
provide a mechanism for how VEGF expression is regulated
pathophysiologically by ERb1 and establish the relevance of
this mechanism to PCa by demonstrating that VEGF-A expres-
sion in PCa correlates with Gleason grade. Moreover, our data
indicate that the expression of HIF-1a itself and HIF-1a target
genes is associated with a mesenchymal, aggressive pheno-
type. We note also an emerging relationship among ERb1,
VEGF and hypoxia. Hypoxia selects for the survival of more
aggressive tumor cells (Brown, 1999) and it induces an EMT as
shown here and previously (Higgins et al., 2007; Lester et al.,
2007). Hypoxia also stimulates VEGF expression (Harris, 2002)
and diminishes ERb1 expression, as we demonstrate. Thus,
hypoxia emerges as one mechanism that facilitates the acquisi-
tion of mesenchymal characteristics in PCa cells by suppressing
ERb1 and stimulating HIF-1a-mediated VEGF expression. Inter-
estingly, a recent study concluded that cells from PCa patients
with a poor prognosis exhibited a hypoxic phenotype (Nanni
et al., 2009).
The ability of ERb1 to control NRP1 function by regulating
VEGF-A expression establishes a connection between this ER
and VEGF receptor signaling. Since the seminal observation
that NRP1 can function as a VEGF receptor (Soker et al., 1998),
studies have demonstrated its functional importance in angio-
genesis and cancer (Guttmann-Raviv et al., 2006). However,
the ability of NRP1 to regulate Snail1 localization is unexpected
and may contribute to the reported association of NRP1 with
PCa progression (Latil et al., 2000; Miao et al., 2000) and tumor
de-differentiation (Cao et al., 2008). Our observation that ERb1
can impact NRP1 function by controlling VEGF expression
adds to our understanding of how this VEGF receptor can be
regulated in cancer. In addition, our identification of a VEGF-A/
NRP1 pathway that is regulated by ERb1, promotes an EMT,
and distinguishes high Gleason grade PCa may be appropriate
and feasible for therapeutic targeting. Adjuvant therapy aimed
at targeting VEGF (bevacizumab) is being used for the clinical
management of several tumors (Ferrara, 2005), and recent data
suggest that NRP antibodies have the potential to have clinical
efficacy (Caunt et al., 2008; Gray et al., 2008; Pan et al., 2007).
Although the overarching assumption had been that such drugs
function by blocking tumor angiogenesis, it is likely that they
also target tumor cells directly, and that patients with high Glea-
son grade PCa may benefit from such anti-VEGF/NRP therapy.
The essence of our study is that 3b-adiol/ERb1 sustain E-cad-
herin transcription and prevent an EMT in PCa cells by seques-
tering Snail1 in the cytoplasm. Although other transcription
factors that regulate E-cadherin may be important for PCa
progression suchasSIP1 (ZEB2) (Konget al., 2009), our data indi-
cate that ERb1 regulates Snail1. The mechanism involved is
linked to the regulation of GSK-3b activity by 3b-adiol/ERb1, an
enzyme that is critical for regulating Snail1 localization and
stability and, as a consequence, the EMT (Bachelder et al.,
2005; Yook et al., 2006; Zhou et al., 2004). The mechanism we
propose for the regulation of Snail1 by ERb1 is distinct from the
regulation of Snail1 by ERa in breast cancer, which involves the
ERa-dependent regulation of MTA3, a repressor of SNAIL1 tran-
scription (Fearon, 2003; Fujita et al., 2003). ERa has also beenreported to impede the EMT and invasiveness of breast cancer
cells by inhibiting the synthesis of RelB (Wang et al., 2007).
Our finding that Snail1 localization is predominantly nuclear in
Gleason grade 5 PCa but largely cytoplasmic in grade 3 PCa is
distinct from other studies that have shown that Snail1 expres-
sion but not localization in other cancers differs among tumor
subtypes or stages (e.g., Blanco et al., 2002; Moody et al.,
2005). A potentially important and useful implication of our
data is that nuclear Snail1 could serve as a biomarker to predict
the propensity of a given tumor to progress to advanced disease.
This possibility is particularly relevant and timely given the uncer-
tainty and ineffectiveness of PSA screening in predicting
outcome (Andriole et al., 2009; Schroder et al., 2009).
In summary, our data contribute to an understanding of the
molecular basis for the Gleason grading system and suggest a
mechanism that promotes for the aggressive and invasive nature
of high Gleason grade tumors.
EXPERIMENTAL PROCEDURES
Clinical Specimens
Tissue samples of defined Gleason grades were obtained from the UMASS
Cancer Center Tissue Bank with approval of the Institutional Review Board
(IRB) of UMASSMedical School. The IRB granted awaiver for obtaining patient
consent in accordance with National Institutes of Health guidelines because
these were pre-existing, deidentified specimens. Tissue microarrays contain-
ing Gleason grade 5 PCa were kindly provided by Dr M. Loda of the Dana
Farber Cancer Institute (Boston, MA). Specimens were stained with Abs
specific for ERb1 (Gene Tex), E-cadherin (Abcam), Snail1 (Abcam), VEGF-A
(R&D Systems), and HIF-1a (Novus). Frozen specimens were microdissected
by laser capture microscopy (Arcturus PixCell 2) as described elsewhere
(Loric et al., 2001) to obtain pure populations of tumor cells of defined
Gleason grades. RNA was isolated from these specimens using the RNeasy
kit (QIAGEN). Additional details on the clinical specimens used and method
of analysis are provided in Supplemental Experimental Procedures.
Cells and Reagents
The human prostate cancer cell lines (LNCaP and PC3) were obtained from
American Type Culture Collection (ATCC: Manassas, VA). TGF-b experiments
were performed by incubating cells with recombinant human TGF-b (5 ng/ml;
Peprotech) for 3-4 days. For hypoxia experiments, cells were grown in a
Ruskinn Hypoxic Chamber (0.5% O2; 5% CO2) for 18-20 hr. The psiSTRIKE
U6 Hairpin Cloning System (Promega) was used for DNA-directed shRNA
expression using sequences optimized for ERb1 (Mak et al., 2006). Cells
were also transfected transiently with On-Target Plus SMARTpool siRNAs
(Dharmacon, CO) for ERb1, ERa, and Snail1. These target sequences have
been published by Dharmacon. Nontargeting pools were used as negative
controls. Lentiviruses (pLKO.1) containing the NRP1 shRNA Oligonucleotide
ID TRCN0000063527 (Open Biosystems, Huntsville, AL) and pLKO.1 empty
vector or pLKO-GFP controls were generated and used to infect PC3 cells
following standard protocols. The reporter gene, p11w, which contains the
wild-type HRE (hypoxia responsive element) and the mutated version, p11m
fused to luciferase, were obtained from ATCC. The E-cadherin promoter
reporter gene (pGL2Basic-EcadK1) andGFPSnailWT plasmidswere obtained
from Addgene. The Renilla-luciferase plasmid was purchased from Promega.
Biochemical Analyses
Total RNA was isolated using the TRI reagent (Sigma) and reverse-transcribed
to cDNA using Superscript II reverse transcriptase (Invitrogen). Details on
primers used and polymerase chain reaction (PCR) methods are provided in
Supplemental Experimental Procedures. For immunoblots, cells were
extracted with RIPA buffer containing EDTA and EGTA (Boston BioProducts)
with a protease inhibitor cocktail, and blots were performed as described
previously (Bae et al., 2008) using primary Abs against ERa, ERb1, E-cadherin,
N-cadherin, vimentin, Snail1, pAkt (Ser473), total Akt, pGSK3b (Ser9), totalCancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc. 327
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Figure 6. ERb1 and EMT Regulate Snail1 Nuclear Localization
(A) PC3 cells that express an ERb1 shRNA were transfected with either a control siRNA (siCon) or Snail1 siRNA (siSnail1), and analyzed for morphology and
expression of EMT markers.
(B) Snail1 was visualized by immunofluorescencemicroscopy in PC3 cellsmaintained in either normoxia (N) or hypoxia (H) for 48 hr. The photomicrographs shown
represent themerged images obtained fromSnail1 staining (green; FITC) and nuclear staining (blue; DAPI). Note that in normoxia, Snail1 staining is predominantly
cytoplasmic and excluded from nuclei. In hypoxia, however, Snail1 localization in nuclei is evidenced by ‘‘whitish-blue’’ staining.
(C) The percentage of nuclei that had Snail1 staining was quantified in PC3 cells maintained in normoxia (N) and hypoxia (H), and in cells stimulated with TGF-b or
VEGF-A, as well as in PC3 cells in which ERb1 or NRP1 expression was depleted by shRNA. Snail1 nuclear localization was also quantified in PC3 cells treated
with LiCl2, a GSK-3b inhibitor. The data represent the mean of 3 separate experiments with SEM and P value (*) < 0.05 indicated.
(D) PC3 cells that express either a scrambled shRNA (Scr) or ERb1 shRNA (shERb1) were transfected with aGFP-Snail1 construct. GFP andDAP1were visualized
and the images merged. Note the nuclear localization of GFP-Snail1 as evidenced by the whitish-blue staining that is associated with loss of ERb1 expression.
The bar graph represents the quantification of nuclear GFP-Snail1 from three independent experiments (± SEM) and p value (*) < 0.05 indicated.
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Figure 7. HIF-1a/VEGF/Snail1 Pathway Is
Manifested in High Gleason Grade PCa
(A–C) Thirty specimens of human PCa including 20
Gleason grade 3 tumors and 10 Gleason grade 5
tumors were immunostained for ERb1 (A), HIF-1a
(B), VEGF-A (C), and Snail1 (E). Semiquantitative
analysis of IHC staining was performed for all
samples that assessed both the percentage of
cells stained and the intensity of the staining, and
this analysis is reported as the Quotient (Q) of
these two parameters (± standard deviation). The
significance of the difference in Q between Glea-
son grade 3 and 5 as determined by Student’s
t test is shown for each bar graph. Photomicro-
graphs representative of the mean Q for each
IHC staining are shown.
(D) Microdissected samples from grade 3 and
grade 5 PCa were analyzed for the expression of
VEGF-A mRNA by qPCR and the data represent
the average of seven separate specimens for
each grade (± SEM). Red scale bars represent
25 mm; black scale bars represent 50 mm.
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ERb Impedes Prostate Carcinoma EMTGSK3b, NRP1, HIF-1a, and b-actin, which were obtained from Santa Cruz
Biotechnology (CA), Sigma (MO), Abcam (MA), or Gene Tex, Inc. (CA). Estra-
diol-17b (E2), 3b-androstane-diol (3b-adiol), and PHTPP were obtained from
Tocris. The proteasome inhibitor MG132 was obtained from Calbiochem.
VEGF-A levels in culture medium were quantified by ELISA (R&D Systems).
Snail1 Localization
For immunofluorescence microscopy, cells were maintained under the condi-
tions described in Figure 3B, fixed with paraformaldehyde, and incubated with
a Snail1 Ab (Abcam, MA) and a fluorescein isothiocyanate-conjugated
secondary Ab (Jackson Immunoresearch, West Grove, PA). Coverslips were
mounted on slideswith SlowFadeAntifade reagent containing DAPI (Molecular
Probes). For localization of exogenous Snail1, cells were transfected with
a GFP-Snail1 construct (Addgene) using Lipofectamine 2000 and analyzed
as described above.
Analysis of VEGF-A Promoter
The VEGF-A promoter was PCR amplified from human genomic DNA. The
PCR-amplified fragment was confirmed by restriction mapping and cloned
at the Xho1-Hind III site into the pGL3 basic vector (Promega). Site-directed(E) PC3 cells were treated with TGB-b in the absence or presence of 3b-adiol (1 mM) and nuclear Snail1 wa
separate experiments with SEM and p value (*) < 0.05 indicated.
Cancer Cell 17, 319–3mutagenesis was used to mutate the ERE
sequence from (AATCAGACTGACT) to (AACTG
GACCAACT) and the HRE sequence from
(TACGTG) to (TAAAAG). Details on this analysis
are provided in Supplemental Experimental
Procedures.
Luciferase Assays
PC3 cells were transfected with the desired plas-
mids and the Renilla luciferase construct to
normalize for transfection efficiency. Relative light
units were calculated as the ratio of Firefly lucif-
erase to Renilla luciferase activity (normalized
luciferase activity). The protocol used for transfec-
tion and measurement of luciferase activity has
been described previously (Mak et al., 2006).
Migration and Invasion Assays
Assays were performed using 6.5 mm Transwell
chambers (8 mm pore size) that had been coatedwith either collagen I or Matrigel (BD Biosciences, Bedford, MA) for migration
and invasion, respectively, as described previously (Shaw et al., 1997). After 5
hr, the cells that had translocated to the lower surface of the filters were fixed in
methanol. The fixed membranes were mounted on glass slides using Vecta-
shield mounting medium containing DAPI (Vector Laboratories, Burlingame,
CA). Assays were quantified by counting the number of stained nuclei in five
independent fields in each Transwell.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.ccr.2010.
02.030.
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Phenotype and Represses a Mesenchymal Phenotype
The interaction of ERb1 with its ligand 3b-adiol represses an EMT by destabi-
lizing HIF-1a and inhibiting VEGF-A transcription. Stimuli that induce an EMT
diminish ERb1 expression resulting in increased VEGF-A expression and the
consequent activation of a VEGF-A/NRP1 signaling pathway that inhibits
GSK-3b and promotes Snail1 nuclear localization.
Cancer Cell
ERb Impedes Prostate Carcinoma EMTassistance, and Drs. Zhong Jiang (UMASS Medical School) and Massimo
Loda (Dana Farber Cancer Institute, Boston, MA) for providing clinical speci-
mens.
Received: September 11, 2009
Revised: December 3, 2009
Accepted: March 1, 2010
Published: April 12, 2010
REFERENCES
Acevedo, V.D., Gangula, R.D., Freeman, K.W., Li, R., Zhang, Y., Wang, F.,
Ayala, G.E., Peterson, L.E., Ittmann, M., and Spencer, D.M. (2007). Inducible
FGFR-1 activation leads to irreversible prostate adenocarcinoma and an
epithelial-to-mesenchymal transition. Cancer Cell 12, 559–571.
Andriole, G.L., Crawford, E.D., Grubb, R.L., III, Buys, S.S., Chia, D., Church,
T.R., Fouad, M.N., Gelmann, E.P., Kvale, P.A., Reding, D.J., et al. (2009).
Mortality results from a randomized prostate-cancer screening trial. N. Engl.
J. Med. 360, 1310–1319.
Bachelder, R.E., Crago, A., Chung, J., Wendt, M.A., Shaw, L.M., Robinson, G.,
and Mercurio, A.M. (2001). Vascular endothelial growth factor is an autocrine
survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res.
61, 5736–5740.
Bachelder, R.E., Yoon, S.O., Franci, C., de Herreros, A.G., and Mercurio, A.M.
(2005). Glycogen synthase kinase-3 is an endogenous inhibitor of Snail
transcription: implications for the epithelial-mesenchymal transition. J. Cell
Biol. 168, 29–33.
Bae, D., Lu, S., Taglienti, C.A., and Mercurio, A.M. (2008). Metabolic stress
induces the lysosomal degradation of neuropilin-1 but not neuropilin-2.
J. Biol. Chem. 283, 28074–28080.
Bates, R.C., Goldsmith, J.D., Bachelder, R.E., Brown, C., Shibuya, M.,
Oettgen, P., and Mercurio, A.M. (2003). Flt-1 (VEGFR-1)-dependent survival
characterizes the epithelial-mesenchymal transition of colonic organoids.
Curr. Biol. 13, 1721–1727.
Blanco, M.J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios,
J., and Nieto, M.A. (2002). Correlation of Snail expression with histological
grade and lymph node status in breast carcinomas. Oncogene 21, 3241–3246.
Brown, J.M. (1999). The hypoxic cell: a target for selective cancer therapy–
eighteenth Bruce F. CainMemorial Award lecture. Cancer Res. 59, 5863–5870.
Buteau-Lozano, H., Ancelin, M., Lardeux, B., Milanini, J., and Perrot-Applanat,
M. (2002). Transcriptional regulation of vascular endothelial growth factor by
estradiol and tamoxifen in breast cancer cells: a complex interplay between
estrogen receptors alpha and beta. Cancer Res. 62, 4977–4984.330 Cancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc.Cao, Y.,Wang, L., Nandy, D., Zhang, Y., Basu, A., Radisky, D., andMukhopad-
hyay, D. (2008). Neuropilin-1 upholds dedifferentiation and propagation
phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog
axes. Cancer Res. 68, 8667–8672.
Castro-Rivera, E., Ran, S., Thorpe, P., and Minna, J.D. (2004). Semaphorin 3B
(SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165
antagonizes this effect. Proc. Natl. Acad. Sci. USA 101, 11432–11437.
Caunt, M., Mak, J., Liang,W.C., Stawicki, S., Pan, Q., Tong, R.K., Kowalski, J.,
Ho, C., Reslan, H.B., Ross, J., et al. (2008). Blocking neuropilin-2 function
inhibits tumor cell metastasis. Cancer Cell 13, 331–342.
Compton, D.R., Sheng, S., Carlson, K.E., Rebacz, N.A., Lee, I.Y.,
Katzenellenbogen, B.S., and Katzenellenbogen, J.A. (2004). Pyrazolo[1,5-a]-
pyrimidines: estrogen receptor ligands possessing estrogen receptor beta
antagonist activity. J. Med. Chem. 47, 5872–5893.
Dhasarathy, A., Kajita, M., andWade, P.A. (2007). The transcription factor snail
mediates epithelial to mesenchymal transitions by repression of estrogen
receptor-alpha. Mol. Endocrinol. 21, 2907–2918.
Doble, B.W., and Woodgett, J.R. (2003). GSK-3: tricks of the trade for a multi-
tasking kinase. J. Cell Sci. 116, 1175–1186.
Dominguez, D., Montserrat-Sentis, B., Virgos-Soler, A., Guaita, S., Grueso, J.,
Porta, M., Puig, I., Baulida, J., Franci, C., and Garcia de Herreros, A. (2003).
Phosphorylation regulates the subcellular location and activity of the snail tran-
scriptional repressor. Mol. Cell. Biol. 23, 5078–5089.
Egevad, L. (2008a). Recent trends in Gleason grading of prostate cancer: I.
Pattern interpretation. Anal. Quant. Cytol. Histol. 30, 190–198.
Egevad, L. (2008b). Recent trends in gleason grading of prostate cancer. II.
Prognosis, reproducibility and reporting. Anal. Quant. Cytol. Histol. 30,
254–260.
Epstein, J.I., Allsbrook, W.C., Jr., Amin, M.B., and Egevad, L.L. (2005). The
2005 International Society of Urological Pathology (ISUP) Consensus Confer-
ence on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 29,
1228–1242.
Fearon, E.R. (2003). Connecting estrogen receptor function, transcriptional
repression, and E-cadherin expression in breast cancer. Cancer Cell 3,
307–310.
Ferrara, N. (2005). VEGF as a therapeutic target in cancer. Oncology 69
(Suppl 3), 11–16.
Fujita, N., Jaye, D.L., Kajita, M., Geigerman, C., Moreno, C.S., and Wade, P.A.
(2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth
pathway in breast cancer. Cell 113, 207–219.
Girault, I., Lerebours, F., Amarir, S., Tozlu, S., Tubiana-Hulin, M., Lidereau, R.,
and Bieche, I. (2003). Expression analysis of estrogen receptor alpha coregu-
lators in breast carcinoma: evidence that NCOR1 expression is predictive of
the response to tamoxifen. Clin. Cancer Res. 9, 1259–1266.
Gleason, D.F., and Mellinger, G.T. (1974). Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging.
J. Urol. 111, 58–64.
Gravdal, K., Halvorsen, O.J., Haukaas, S.A., and Akslen, L.A. (2007). A switch
from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal
transition and is of strong and independent importance for the progress of
prostate cancer. Clin. Cancer Res. 13, 7003–7011.
Gray, M.J., Van Buren, G., Dallas, N.A., Xia, L., Wang, X., Yang, A.D., Somcio,
R.J., Lin,Y.G., Lim,S., Fan, F., et al. (2008). Therapeutic targetingof neuropilin-2
on colorectal carcinoma cells implanted in themurine liver. J. Natl. Cancer Inst.
100, 109–120.
Guerini, V., Sau, D., Scaccianoce, E., Rusmini, P., Ciana, P., Maggi, A., Martini,
P.G., Katzenellenbogen, B.S., Martini, L., Motta, M., and Poletti, A. (2005). The
androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate
cancer cell migration through activation of the estrogen receptor beta subtype.
Cancer Res. 65, 5445–5453.
Guttmann-Raviv, N., Kessler, O., Shraga-Heled, N., Lange, T., Herzog, Y., and
Neufeld, G. (2006). The neuropilins and their role in tumorigenesis and tumor
progression. Cancer Lett. 231, 1–11.
Cancer Cell
ERb Impedes Prostate Carcinoma EMTHarris, A.L. (2002). Hypoxia–a key regulatory factor in tumour growth. Nat. Rev.
Cancer 2, 38–47.
Higgins, D.F., Kimura, K., Bernhardt, W.M., Shrimanker, N., Akai, Y.,
Hohenstein, B., Saito, Y., Johnson, R.S., Kretzler, M., Cohen, C.D., et al.
(2007). Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithe-
lial-to-mesenchymal transition. J. Clin. Invest. 117, 3810–3820.
Horvath, L.G., Henshall, S.M., Lee, C.S., Head, D.R., Quinn, D.I., Makela, S.,
Delprado, W., Golovsky, D., Brenner, P.C., O’Neill, G., et al. (2001). Frequent
loss of estrogen receptor-beta expression in prostate cancer. Cancer Res.
61, 5331–5335.
Hyder, S.M. (2006). Sex-steroid regulation of vascular endothelial growth
factor in breast cancer. Endocr. Relat. Cancer 13, 667–687.
Imamov, O., Morani, A., Shim, G.J., Omoto, Y., Thulin-Andersson, C., Warner,
M., and Gustafsson, J.A. (2004). Estrogen receptor beta regulates epithelial
cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci.
USA 101, 9375–9380.
Kong, D., Li, Y., Wang, Z., Banerjee, S., Ahmad, A., Kim, H.R., and Sarkar, F.H.
(2009). miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transi-
tion, adhesion, and invasion of prostate cancer cells. Stem Cells 27,
1712–1721.
Kuiper, G.G., and Gustafsson, J.A. (1997). The novel estrogen receptor-beta
subtype: potential role in the cell- and promoter-specific actions of estrogens
and anti-estrogens. FEBS Lett. 410, 87–90.
Kuiper, G.G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S.,
and Gustafsson, J.A. (1997). Comparison of the ligand binding specificity and
transcript tissue distribution of estrogen receptors alpha and beta. Endocri-
nology 138, 863–870.
Latil, A., Bieche, I., Pesche, S., Valeri, A., Fournier, G., Cussenot, O., and
Lidereau, R. (2000). VEGF overexpression in clinically localized prostate
tumors and neuropilin-1 overexpression in metastatic forms. Int. J. Cancer
89, 167–171.
Lau, K.M., LaSpina, M., Long, J., and Ho, S.M. (2000). Expression of estrogen
receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial
cells: regulation by methylation and involvement in growth regulation. Cancer
Res. 60, 3175–3182.
Leav, I., Lau, K.M., Adams, J.Y., McNeal, J.E., Taplin, M.E., Wang, J., Singh,
H., and Ho, S.M. (2001). Comparative studies of the estrogen receptors beta
and alpha and the androgen receptor in normal human prostate glands,
dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159,
79–92.
Lester, R.D., Jo, M., Montel, V., Takimoto, S., and Gonias, S.L. (2007). uPAR
induces epithelial-mesenchymal transition in hypoxic breast cancer cells.
J. Cell Biol. 178, 425–436.
Leung, Y.K., Mak, P., Hassan, S., and Ho, S.M. (2006). Estrogen receptor (ER)-
beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci.
USA 103, 13162–13167.
Liao, D., and Johnson, R.S. (2007). Hypoxia: a key regulator of angiogenesis in
cancer. Cancer Metastasis Rev. 26, 281–290.
Lim, W., Cho, J., Kwon, H.Y., Park, Y., Rhyu, M.R., and Lee, Y. (2009).
Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied
estrogen receptor beta. FEBS Lett. 583, 1314–1318.
Loric, S., Paradis, V., Gala, J.L., Berteau, P., Bedossa, P., Benoit, G., and
Eschwege, P. (2001). Abnormal E-cadherin expression and prostate cell blood
dissemination asmarkers of biological recurrence in cancer. Eur. J. Cancer 37,
1475–1481.
Mak, P., Leung, Y.K., Tang, W.Y., Harwood, C., and Ho, S.M. (2006). Apigenin
suppresses cancer cell growth through ERbeta. Neoplasia 8, 896–904.
Miao, H.Q., Lee, P., Lin, H., Soker, S., and Klagsbrun, M. (2000). Neuropilin-1
expression by tumor cells promotes tumor angiogenesis and progression.
FASEB J. 14, 2532–2539.
Moody, S.E., Perez, D., Pan, T.C., Sarkisian, C.J., Portocarrero, C.P., Sterner,
C.J., Notorfrancesco, K.L., Cardiff, R.D., and Chodosh, L.A. (2005). The tran-
scriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell
8, 197–209.Morani, A., Warner, M., and Gustafsson, J.A. (2008). Biological functions and
clinical implications of oestrogen receptors alfa and beta in epithelial tissues.
J. Intern. Med. 264, 128–142.
Nanni, S., Benvenuti, V., Grasselli, A., Priolo, C., Aiello, A., Mattiussi, S.,
Colussi, C., Lirangi, V., Illi, B., D’Eletto, M., et al. (2009). Endothelial NOS,
estrogen receptor beta, and HIFs cooperate in the activation of a prognostic
transcriptional pattern in aggressive human prostate cancer. J. Clin. Invest.
119, 1093–1108.
Oliveira, A.G., Coelho, P.H., Guedes, F.D., Mahecha, G.A., Hess, R.A., and
Oliveira, C.A. (2007). 5alpha-Androstane-3beta,17beta-diol (3beta-diol), an
estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator
of estrogen receptor ERbeta expression in the ventral prostrate of adult rats.
Steroids 72, 914–922.
Pan, Q., Chanthery, Y., Liang, W.C., Stawicki, S., Mak, J., Rathore, N., Tong,
R.K., Kowalski, J., Yee, S.F., Pacheco, G., et al. (2007). Blocking neuropilin-1
function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer
Cell 11, 53–67.
Prins, G.S., and Korach, K.S. (2008). The role of estrogens and estrogen recep-
tors in normal prostate growth and disease. Steroids 73, 233–244.
Prins, G.S., Marmer, M., Woodham, C., Chang, W., Kuiper, G., Gustafsson,
J.A., and Birch, L. (1998). Estrogen receptor-beta messenger ribonucleic
acid ontogeny in the prostate of normal and neonatally estrogenized rats.
Endocrinology 139, 874–883.
Pritchard, C., Mecham, B., Dumpit, R., Coleman, I., Bhattacharjee, M., Chen,
Q., Sikes, R.A., and Nelson, P.S. (2009). Conserved gene expression programs
integrate mammalian prostate development and tumorigenesis. Cancer Res.
69, 1739–1747.
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen,
V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009). Screening and
prostate-cancer mortality in a randomized European study. N. Engl. J. Med.
360, 1320–1328.
Shaw, L.M., Rabinovitz, I., Wang, H.H., Toker, A., and Mercurio, A.M. (1997).
Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin
promotes carcinoma invasion. Cell 91, 949–960.
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., and Klagsbrun, M. (1998).
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-
specific receptor for vascular endothelial growth factor. Cell 92, 735–745.
Stevens, A., Soden, J., Brenchley, P.E., Ralph, S., and Ray, D.W. (2003).
Haplotype analysis of the polymorphic human vascular endothelial growth
factor gene promoter. Cancer Res. 63, 812–816.
Stoner, M., Wormke, M., Saville, B., Samudio, I., Qin, C., Abdelrahim, M., and
Safe, S. (2004). Estrogen regulation of vascular endothelial growth factor gene
expression in ZR-75 breast cancer cells through interaction of estrogen
receptor alpha and SP proteins. Oncogene 23, 1052–1063.
Su, J.L., Yang, P.C., Shih, J.Y., Yang, C.Y., Wei, L.H., Hsieh, C.Y., Chou, C.H.,
Jeng, Y.M., Wang, M.Y., Chang, K.J., et al. (2006). The VEGF-C/Flt-4 axis
promotes invasion and metastasis of cancer cells. Cancer Cell 9, 209–223.
Tomita, K., van Bokhoven, A., van Leenders, G.J., Ruijter, E.T., Jansen, C.F.,
Bussemakers, M.J., and Schalken, J.A. (2000). Cadherin switching in human
prostate cancer progression. Cancer Res. 60, 3650–3654.
Trpkov, K., Zhang, J., Chan, M., Eigl, B.J., and Yilmaz, A. (2009). Prostate
cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopath-
ologic findings and disease progression. Am. J. Surg. Pathol. 33, 233–240.
Voigt, K.D., and Bartsch, W. (1986). Intratissular androgens in benign prostatic
hyperplasia and prostatic cancer. J. Steroid Biochem. 25, 749–757.
Wanami, L.S., Chen, H.Y., Peiro, S., Garcia de Herreros, A., and Bachelder,
R.E. (2008). Vascular endothelial growth factor-A stimulates Snail expression
in breast tumor cells: implications for tumor progression. Exp. Cell Res. 314,
2448–2453.
Wang, X., Belguise, K., Kersual, N., Kirsch, K.H., Mineva, N.D., Galtier, F.,
Chalbos, D., and Sonenshein, G.E. (2007). Oestrogen signalling inhibits inva-
sive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol. 9,
470–478.Cancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc. 331
Cancer Cell
ERb Impedes Prostate Carcinoma EMTWu, Y., Deng, J., Rychahou, P.G., Qiu, S., Evers, B.M., and Zhou, B.P. (2009).
Stabilization of snail by NF-kappaB is required for inflammation-induced cell
migration and invasion. Cancer Cell 15, 416–428.
Yang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: at the
crossroads of development and tumor metastasis. Dev. Cell 14, 818–829.
Yang, A.D., Camp, E.R., Fan, F., Shen, L., Gray, M.J., Liu, W., Somcio, R.,
Bauer, T.W., Wu, Y., Hicklin, D.J., and Ellis, L.M. (2006). Vascular endothelial
growth factor receptor-1 activation mediates epithelial to mesenchymal tran-
sition in human pancreatic carcinoma cells. Cancer Res. 66, 46–51.
Yook, J.I., Li, X.Y., Ota, I., Fearon, E.R., andWeiss, S.J. (2005). Wnt-dependent
regulation of the E-cadherin repressor snail. J. Biol. Chem. 280, 11740–11748.332 Cancer Cell 17, 319–332, April 13, 2010 ª2010 Elsevier Inc.Yook, J.I., Li, X.Y., Ota, I., Hu, C., Kim, H.S., Kim, N.H., Cha, S.Y., Ryu, J.K.,
Choi, Y.J., Kim, J., et al. (2006). A Wnt-Axin2-GSK3beta cascade regulates
Snail1 activity in breast cancer cells. Nat. Cell Biol. 8, 1398–1406.
Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gunduz, M., and Hung, M.C.
(2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in
control of epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931–940.
Zhu, X., Leav, I., Leung, Y.K., Wu, M., Liu, Q., Gao, Y., McNeal, J.E., and
Ho, S.M. (2004). Dynamic regulation of estrogen receptor-beta expression
by DNA methylation during prostate cancer development and metastasis.
Am. J. Pathol. 164, 2003–2012.
